Corestemchemon Inc

Corestemchemon Inc has a market price of 4,480 KRW per share and a market capitalization of 215,467,060,480 KRW, with a price-to-book ratio of 3.91 and a price-to-tangible-book ratio of 3.91. The company's enterprise value to EBITDA is -9.54, and its enterprise value to revenue is 12.56. The company's return on equity is -48.63%, and its return on assets is -23.88%. The debt-to-equity ratio is 0.71, and the current ratio is 0.46, indicating a liquidity risk. The company's profitability is negative, with a net loss of 26,833,142,830 KRW and an operating loss of 26,533,499,620 KRW. The gross profit is also negative at -4,070,152,090 KRW. These figures are below the industry median for profitability metrics, suggesting underperformance relative to peers. The company's return on equity and return on assets are significantly negative, indicating poor capital efficiency and asset utilization. Corestemchemon Inc operates through two segments: the Non-clinical CRO Business and the Cell Therapy Business. The Cell Therapy Business focuses on treatments for Lou Gehrig's disease, such as Neuronata-R. The company's geographic exposure is primarily concentrated in South Korea, with no disclosed international revenue segments. The lack of geographic diversification increases the company's exposure to local economic and regulatory risks. The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year. The operating cash flow is negative at -13,866,551,050 KRW, and the free cash flow is -24,730,986,570 KRW. The capital expenditure is -2,055,504,740 KRW, indicating ongoing investment in operations. The company's liquidity risk is rated as medium, and its net cash position is negative after subtracting total debt. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag is the negative net cash position after subtracting total debt, which could impact the company's ability to meet short-term obligations. The dilution risk is low, with no near-term pressure expected. The company's capital structure is supported by total assets of 112,371,324,320 KRW and total liabilities of 57,197,895,120 KRW. Recent events include the company's rebranding from Corestem Inc to Corestemchemon Inc, reflecting its expanded focus on stem cell therapies. The company has disclosed ongoing research and development activities in its Non-clinical CRO Business and Cell Therapy Business segments. No recent filings or transcripts indicate significant changes in the company's strategic direction or financial outlook.